Rouven Nietsch
Overview
Explore the profile of Rouven Nietsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
516
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shirvani Samani O, Scherr J, Kayvanpour E, Haas J, Lehmann D, Gi W, et al.
J Clin Med
. 2022 Jan;
11(1).
PMID: 35011745
Background: The current gold standard biomarker for myocardial infarction (MI), cardiac troponin (cTn), is recognized for its high sensitivity and organ specificity; however, it lacks diagnostic specificity. Numerous studies have...
2.
Haas J, Frese K, Sedaghat-Hamedani F, Kayvanpour E, Tappu R, Nietsch R, et al.
Int J Mol Sci
. 2021 Mar;
22(4).
PMID: 33670449
With more than 25 million people affected, heart failure (HF) is a global threat. As energy production pathways are known to play a pivotal role in HF, we sought here...
3.
Jakobi T, Siede D, Eschenbach J, Heumuller A, Busch M, Nietsch R, et al.
Cells
. 2020 Jul;
9(7).
PMID: 32635460
For decades, cardiovascular disease (CVD) has been the leading cause of death throughout most developed countries. Several studies relate RNA splicing, and more recently also circular RNAs (circRNAs), to CVD....
4.
Kayvanpour E, Gi W, Sedaghat-Hamedani F, Lehmann D, Frese K, Haas J, et al.
J Mol Cell Cardiol
. 2020 Apr;
151:155-162.
PMID: 32305360
Background: Cardiac troponins are the preferred biomarkers of acute myocardial infarction. Despite superior sensitivity, serial testing of Troponins to identify patients suffering acute coronary syndromes is still required in many...
5.
Haas J, Mester S, Lai A, Frese K, Sedaghat-Hamedani F, Kayvanpour E, et al.
EMBO Mol Med
. 2017 Nov;
10(1):107-120.
PMID: 29138229
The transcriptome needs to be tightly regulated by mechanisms that include transcription factors, enhancers, and repressors as well as non-coding RNAs. Besides this dynamic regulation, a large part of phenotypic...
6.
Meder B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Frese K, Lai A, et al.
Circulation
. 2017 Aug;
136(16):1528-1544.
PMID: 28838933
Background: Biochemical DNA modification resembles a crucial regulatory layer among genetic information, environmental factors, and the transcriptome. To identify epigenetic susceptibility regions and novel biomarkers linked to myocardial dysfunction and...
7.
Nietsch R, Haas J, Lai A, Oehler D, Mester S, Frese K, et al.
Genomics Proteomics Bioinformatics
. 2016 Aug;
14(4):200-6.
PMID: 27475404
Next-generation sequencing (NGS) is getting routinely used in the diagnosis of hereditary diseases, such as human cardiomyopathies. Hence, it is of utter importance to secure high quality sequencing data, enabling...
8.
Haas J, Frese K, Peil B, Kloos W, Keller A, Nietsch R, et al.
Eur Heart J
. 2014 Aug;
36(18):1123-35a.
PMID: 25163546
Aim: Numerous genes are known to cause dilated cardiomyopathy (DCM). However, until now technological limitations have hindered elucidation of the contribution of all clinically relevant disease genes to DCM phenotypes...
9.
Haas J, Frese K, Park Y, Keller A, Vogel B, Lindroth A, et al.
EMBO Mol Med
. 2013 Jan;
5(3):413-29.
PMID: 23341106
Dilated cardiomyopathies (DCM) show remarkable variability in their age of onset, phenotypic presentation, and clinical course. Hence, disease mechanisms must exist that modify the occurrence and progression of DCM, either...